DIAMEDICA THERAPEUTICS INC (DMAC) — insider trading
Health Care · NASDAQ
DIAMEDICA THERAPEUTICS INC (DMAC) has 12 reported SEC Form 4 insider transactions in our data (latest 2026-06-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Krop Julie | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 67,500 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Kellen Scott | Officer (CFO & Secretary) | Grant / award / vesting (derivative) | 162,000 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Pauls Dietrich John | Director, Officer (President & CEO) | Grant / award / vesting (derivative) | 380,000 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Parsons James T. | Director | Grant / award / vesting (derivative) | 51,189 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Semba Charles Pauling | Director | Grant / award / vesting (derivative) | 40,412 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Lewis Tanya | Director | Grant / award / vesting (derivative) | 40,412 | $0.00 | $0 | Form 4 |
| 2026-06-01 | O'Connor Daniel J. | Director | Grant / award / vesting (derivative) | 40,412 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Kuntz Richard | Director | Grant / award / vesting (derivative) | 40,412 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Giuffre Randall Michael | Director | Grant / award / vesting (derivative) | 40,412 | $0.00 | $0 | Form 4 |
| 2026-01-02 | Semba Charles Pauling | Director | Grant / award / vesting | 3,355 | $8.42 | $28.2K | Form 4 |
| 2026-01-02 | Giuffre Randall Michael | Director | Grant / award / vesting | 6,175 | $8.42 | $52.0K | Form 4 |
| 2026-01-02 | Parsons James T. | Director | Grant / award / vesting | 10,095 | $8.42 | $85.0K | Form 4 |
Ask the chat about DMAC's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: DIAMEDICA THERAPEUTICS INC (DMAC).
Last updated 2026-06-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.